Skip to main navigation

Back to SpringWorksTx.com
Investors & Media
Contact Us
Linkedin
Twitter

Overview
News & Events
- Press Releases
- Events & Presentations
Corporate Governance
Financial Information
- SEC Filings
- Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
Investors + Media
Medical Professionals
Contact Us
Linkedin
Twitter

Press Releases

Items Per Page

Year

27 Oct 2021

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

PDF Version

20 Oct 2021

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

PDF Version

20 Oct 2021

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

PDF Version

07 Sep 2021

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PDF Version

30 Aug 2021

SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

PDF Version

04 Aug 2021

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

PDF Version

03 Aug 2021

SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

PDF Version

03 Aug 2021

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

PDF Version

27 Jul 2021

SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

PDF Version

20 Jul 2021

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

PDF Version

Pagination

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Displaying 81 - 90 of 159

Springworks - Toolkits

Print Page
Email Alerts
RSS Feeds
Investor Contacts

Request E-mail Alerts

Social Links

Footer 1

Who We Are
Focus Areas

Footer 2

Pipeline
Careers
- View Opportunities

Footer 3

Patients
Contact

Footer 4

Investors & Media

© 2025 SpringWorks Therapeutics. All rights reserved.

Copyright Links

Privacy Policy
Terms of Use
Cookie Policy